1 line
17 KiB
Plaintext
1 line
17 KiB
Plaintext
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T05:52:44Z","timestamp":1672638764842},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rofo"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n Background\u2002Percutaneous hepatic perfusion (CS-PHP) is a treatment option for primary and secondary liver neoplasms and subject of intensive research. This present article provides an overview of CS-PHP regarding patient safety, feasibility and effectiveness based on recent studies.<\/jats:p><jats:p>\n Method\u2002We performed a PubMed search including the search terms chemosaturation, hepatic chemosaturation, percutaneous perfusion and melphalan.<\/jats:p><jats:p>\n Results and conclusion\u2002CS-PHP is a promising procedure for the treatment of uveal melanoma and cholangiocellular carcinoma. There are insufficient data regarding the effectiveness of CS-PHP with respect to other tumor entities. Since CS-PHP can be accompanied by multiple transient side effects and complications, close interdisciplinary cooperation is necessary.<\/jats:p><jats:p>\n Key Points:\n <\/jats:p><jats:p>\n Citation Format\n <\/jats:p>","DOI":"10.1055\/a-1858-3418","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T23:11:03Z","timestamp":1660777863000},"page":"30-37","source":"Crossref","is-referenced-by-count":0,"title":["Chemosaturation of the Liver \u2013 an Update"],"prefix":"10.1055","volume":"195","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-6856-6455","authenticated-orcid":false,"given":"Sebastian","family":"Ebel","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0070-3406","authenticated-orcid":false,"given":"Manuel Florian","family":"Struck","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr An\u00e4sthesiologie und Intensivtherapie, Leipzig University, Leipzig, Germany"}]},{"given":"Florian","family":"van Boemmel","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, Sektion f\u00fcr Hepatologie, Leipzig University, Leipzig, Germany"}]},{"given":"Anne Bettina","family":"Beeskow","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany"}]},{"given":"Holger","family":"G\u00f6\u00dfmann","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany"}]}],"member":"194","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","article-title":"Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems\u2019 Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial","volume":"42","author":"T S Meijer","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00270-019-02243-4","article-title":"Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter","volume":"42","author":"C LA Dewald","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10585-020-10057-9","article-title":"Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery","volume":"37","author":"C LA Dewald","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254817","article-title":"Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery","volume":"16","author":"M F Struck","year":"2021","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","article-title":"Prospective Clinical and Pharmacological Evaluation of the Delcath System\u2019s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan","volume":"40","author":"E M de Leede","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jso.23501","article-title":"Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience","volume":"109","author":"M R Forster","year":"2014","journal-title":"J Surg Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1055\/a-1348-1932","article-title":"Chemosaturation with Percutaneous Hepatic Perfusion: Outcome\u00a0and Safety in Patients with Metastasized Uveal Melanoma","volume":"193","author":"C LA Dewald","year":"2021","journal-title":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der Bildgeb Verfahren"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease","volume":"117","author":"I Karydis","year":"2018","journal-title":"J Surg Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","article-title":"Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival","volume":"29","author":"S Marquardt","year":"2019","journal-title":"Eur Radiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study","volume":"40","author":"T J Vogl","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5672048","article-title":"Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan \u2013 Long-Term Overall Survival Negatively Correlates with Tumor Burden","volume":"2020","author":"R Br\u00fcning","year":"2020","journal-title":"Radiol Res Pract"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00432-020-03289-5","article-title":"Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma","volume":"146","author":"L Sch\u00f6nfeld","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1055\/s-0034-1366081","article-title":"Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers","volume":"186","author":"T J Vogl","year":"2014","journal-title":"Rofo"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: A single center experience","volume":"19","author":"C Artzner","year":"2019","journal-title":"Cancer Imaging"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases","volume":"23","author":"M S Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1021\/nn2045246.Multifunctional","article-title":"Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies","volume":"23","author":"J F Pingpank","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","article-title":"Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors","volume":"143","author":"M M Kirstein","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1073274820983019","article-title":"Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases","volume":"27","author":"M J Carr","year":"2020","journal-title":"Cancer Control"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010070","article-title":"A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System","volume":"10","author":"P F Ferrucci","year":"2021","journal-title":"Cells"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1245\/ASO.2004.07.004","article-title":"Regional treatment options for patients with ocular melanoma metastatic to the liver","volume":"11","author":"E D Feldman","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"ref23","first-page":"1230","article-title":"Ocular melanoma: An overview of the current status","volume":"6","author":"P Jovanovic","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","article-title":"Survival of Patents with Metastases from Uveal Melanoma","volume":"98","author":"E S Gragoudas","year":"1991","journal-title":"Ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: Treatment options and future prospects","volume":"101","author":"R D Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28","volume":"124","author":"B S Hawkins","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000367715","article-title":"Adjuvant Therapy of Uveal Melanoma: Current Status","volume":"1","author":"P L Triozzi","year":"2015","journal-title":"Ocul Oncol Pathol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"9567","DOI":"10.1200\/JCO.2016.34.15\\_suppl.9567","article-title":"Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative","volume":"34","author":"L Khoja","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COC.0000000000000109","article-title":"Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy","volume":"40","author":"M Xing","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/CMR.0000000000000051","article-title":"Hepatic yttrium-90 radioembolization for metastatic melanoma: A single-center experience","volume":"24","author":"K Memon","year":"2014","journal-title":"Melanoma Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/COC.0b013e3181b4b065","article-title":"Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: Response, survival, and prognostic factors","volume":"33","author":"S Gupta","year":"2010","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/07357907.2010.535052","article-title":"Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma","volume":"29","author":"J Ahrar","year":"2011","journal-title":"Cancer Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective Phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"C F Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"S A Khan","year":"2019","journal-title":"Liver Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, Version 2.2021","volume":"19","author":"A B Benson","year":"2021","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2013 evolving concepts and therapeutic strategies","volume":"15","author":"S Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1072-7515(01)01016-X","article-title":"Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared","volume":"193","author":"S M Weber","year":"2001","journal-title":"J Am Coll Surg"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"W R Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"J Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4254\/wjh.v12.i10.693","article-title":"Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma","volume":"12","author":"C Akateh","year":"2020","journal-title":"World J Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"LBA8512","DOI":"10.1200\/jco.2010.28.18\\_suppl.lba8512","article-title":"A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma","volume":"28","author":"J F Pingpank","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref44","first-page":"10","article-title":"Vorhersage des Tumoransprechens und Gesamt\u00fcberleben nach Chemosaturation bei hepatisch metastasiertem Aderhautmelanom","volume":"1","author":"A Estler","year":"2021","journal-title":"R\u00f6Fo \u2013 Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der Bildgeb Verfahren"}],"container-title":["R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1858-3418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T23:39:48Z","timestamp":1672616388000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1858-3418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":40,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,1]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"http:\/\/dx.doi.org\/10.1055\/a-1858-3418","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1438-9029","1438-9010"],"issn-type":[{"value":"1438-9029","type":"print"},{"value":"1438-9010","type":"electronic"}],"subject":["Radiology, Nuclear Medicine and imaging"],"published":{"date-parts":[[2022,8,17]]}}} |